At Paragonix our mission is to create a new standard for organ preservation and transport that improves patient outcomes worldwide. We strive to protect the ultimate donation with the dignity and safety it deserves to give patients every possible advantage to thrive. Paragonix SherpaPak® Cardiac Transport System has preserved over 800 hearts since start of clinical use in 2018. Currently the only FDA cleared and CE marked preservation device for heart transportation, Paragonix SherpaPak CTS provides a sterile, temperature and pressurecontrolled environment for organs traveling between operating...

DELIVERING A NEW STANDARD IN HEART PRESERVATION & TRANSPORT

HISTORIC STANDARD OF CARE STORAGE PROBLEM Unpredictable Myocardial Cooling CAUSE Rapid Temperature Decrease to Below 2°C RESULT • Multi-center clinical study found average organ temperature during ice cooler transportation (n=186) was below 2°C and below 0°C after 6 hours1 • Preclinical porcine study found apex temperature below 2°C in 30 minutes and ventricle below 2°C in 150 minutes2 • Preclinical canine study found right ventricle, left ventricle and septum below 1°C in 75 minutes and below 0°C in 4 hours3 KNOWN RISKS BELOW 2°C < 2°C: Cold injury4-7 < 1°C: Irreversible suppression of diastolic...

PGD PREVALENCE & RISK FACTORS PGD REPRESENTS A SIGNIFICANT EXPENSE • 31% (99) classified as PGD • 12% (39) severe PGD & required MCS Study of 317 patients over 5 year period Ischemic Time as a Risk Factor • PGD associated with longer median donor ischemic time (3.2 vs 2.8 hours, P < 0.001) • 1.8x greater risk of PGD for each additional hour (P < 0.001; 95% CI 1.37 - 2.42) MCS average cost $324,226 +/-140,751 No MCS average cost $156,793+/-47,359 Total cost for patients requiring MCS over 2 years Of patients required MCS for PGD but accounted for... ISHLT DONOR HEART PROCUREMENT CONSENSUS • Avoid...

PARAGONIX SHERPAPAK® CARDIAC TRANSPORT SYSTEM TEMPERATURE PROBE Continuous monitoring of temperature PURGE MECHANISM Enables flushing system to remove trapped air pockets for even cooling HEART CONNECTOR Four sizes of heart connector to fully suspend heart immersed in preservation solution NESTED CANISTER SYSTEM Pressure controlled and leak-proof rigid canister to safeguard heart PARAGONIX SHERPACOOL® RIBBONS AND POUCH Consistent storage environment validated to maintain temperature over 40 hours SHIPPER WITH TELESCOPING HANDLE AND WHEELS Light-weight, easy to handle system design to fit in standard...

FOLLOW YOUR TRANSPLANT'S JOURNEY FROM BEGINNING TO END Real-time, centralized, secure coordination for transplant teams including pairing with the Paragonix organ transport systems to share organ status with the entire team ORGAN STATUS Bluetooth pairing to track organ conditions ® CASE STATUS GPS tracking of procurement team en route from the donor center HIPAA compliant messaging and communications to keep the procurement team, OPO, donor hospital, and recipient team informed At-a-glance graphic status trackers provide a snapshot summary of timing of key events in the transplant

GUARDIAN CLINICAL RESULTS First Report of the GUARDIAN Registry: An International Consortium Examining the Effect of Controlled Hypothermic Preservation in Heart Transplantation D.D'Alessandro, J.Philpott, T. Boeve, S. Pham, A. Zuckermann KEY FINDINGS Heart preservation utilizing the Paragonix SherpaPak CTS compares favorably to ice storage in this registry analysis • • • Early clinical outcomes, including PGD rates and ICU length of stay are improved despite unfavorable donor and recipient characteristics Mid-term survival is maintained despite these important differences Additional patients...

GUARDIAN CLINICAL RESULTS PATIENTS WITH >3 HOURS TOTAL ISCHEMIC TIME Ischemic Time Analysis Data demonstrated that a controlled hypothermic transport system provides reliable preservation for cardiac allografts especially when longer ischemic times are required Ischemic Time Total Ischemic Time (mins) Cases utilizing the Paragonix Sherpapak CTS showed a significant decrease of proportion of patients discharged from the ICU in 2 weeks or more (p=0.048) and significantly increased the number of patients discharged in under a week (p=0.0002) Significantly longer ischemic time (31 minutes longer...

GUARDIAN CLINICAL RESULTS Impact Multiple Stages of The Transplant Process Figures represent the percentage difference observed between transplant recipients of donor hearts preserved by Paragonix SherpaPak CTS and ice storage, as reported in the GUARDIAN registry POST TRANSPLANT Total Ischemic Time *Numerical trend, does not achieve statistically significance, p=0.067 **Numerical trend, does not achieve statistically significance, p=0.071

GUARDIAN CLINICAL RESULTS PROGRAM GROWTH Post-Operative Cost Benefit Analysis GAURDIAN registry data was analyzed to evaluate post-operative cost differences from improvements in clinical outcomes and their associated reductions in clinical interventions IN AVERAGE SAVINGS PER PATIENT (P=0.046) Cost Differences: Paragonix Sherpapak vs Ice Storage ICU COSTS P=0.049 TOTAL COSTS TOTAL COSTS Centers around the world have reported the ability to access more donor hearts at greater distances. A major center in California grew to a record number of transplants and expanded their reach to Alaska, Missouri,...

References 1. Horch et al., Transplant Proceed 2002 2. Validation data on file with Paragonix Technologies 3. Hendry et al., J Thorac and Cardiovasc Surg 1989 4. Michel et al. Ann Transplant 2014 5. Michel et al. Ann Transplant 2015 6. Ingemansson et al., Ann Thorac Surg 1996 7. Mankad et al., J Thorac and Cardiovasc Surg 1992 8. Keon et al., Ann Thorac Surg 1988 9. Nicoara et al., Am J Transplant 2016 10. Ali et al., J Heart and Lung Transplant 2015 11. Copeland et al., J Heart Lung Transplant 2020 12. D’Alessandro et al., ISHLT 2021 Presentation 13. Data on file 14. Teuteberg, CareDx Innovation...